Skip to main content
NewslettersWatchlist

Rhythm Pharmaceuticals Inc(RYTM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low62.88
Day High67.61
Open:63.07
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
GlobeNewswire
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
GlobeNewswire
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
GlobeNewswire
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
GlobeNewswire
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
PR Newswire
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
Motley Fool
What Will Amgen Buy Next?
Motley Fool
3 Breakout Growth Stocks to Buy for the Long Haul
Barchart
Stocks Mixed As Fed Rate Hike Looms
Motley Fool
3 Healthcare Stocks That Are Beating the Market
Motley Fool
What Bear Market? These 3 Stocks Have Been Rocketing Higher in 2022
Globe Newswire
Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference
Motley Fool
Why Rhythm Pharmaceuticals Stock Is Rocketing Higher Today
Globe Newswire
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
Globe Newswire
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France
Globe Newswire
NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency
Globe Newswire
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity
Globe Newswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Globe Newswire
Rhythm Pharmaceuticals Launches IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency
Globe Newswire
Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE® (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment
Barchart
Stocks Bounce Back Ahead of Today’s Triple-Witching Expiry

Profile

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.